SCHEMBL879829

SCHEMBL879829

Cc1cc(CO)cc(C)c1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.42
SHBG P04278 1/20 0.40
ALDH1A1 P00352 4/20 0.35
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
LMNA P02545 1/20 0.34
HSD17B10 Q99714 3/20 0.33
TSHR P16473 2/20 0.33
ALOX15 P16050 2/20 0.33
HPGD P15428 1/20 0.33
MAPT P10636 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CASP6 P55212 1/20 0.32
DRD3 P35462 1/20 0.32
CYP2A6 P11509 1/20 0.32
CYP1A2 P05177 1/20 0.31
CASP7 P55210 1/20 0.31
HIF1A Q16665 1/20 0.31
CYP4F2 P78329 1/20 0.31
CYP4A11 Q02928 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22452366 0.88 ACHE (0.37) ACHESHBGALDH1A1ESR1ESR2
SCHEMBL29545312 0.84 ACHE (0.34) ACHESHBGCYP4F2CYP4A11
SCHEMBL24357674 0.84 ACHE (0.34) ACHESHBGCYP4F2CYP4A11
SCHEMBL17694496 0.81 HSD17B10 (0.46) ALDH1A1HSD17B10TSHRALOX15MAPT
SCHEMBL15262317 0.80 TDP1 (0.37) SHBGALDH1A1ESR1ESR2LMNA
SCHEMBL9369186 0.78 ACHE (0.37) ACHESHBGALDH1A1ESR1ESR2
SCHEMBL95656 0.78 ACHE (0.46) ACHESHBGALDH1A1ESR1ESR2
SCHEMBL15262435 0.77 TNKS2 (0.43) SHBGALDH1A1LMNATSHRHPGD
SCHEMBL8630814 0.76 PTGS2 (0.36) ALDH1A1ESR1ESR2LMNAHSD17B10
SCHEMBL13199148 0.76 ACHE (0.43) ACHESHBGALDH1A1ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024059186-A1 N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-03-21 WO disclosed
US-20230373932-A1 DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2023-11-23 US disclosed
EP-3960735-B1 QUINAZOLINE DERIVATIVES USED TO TREAT HIV GILEAD SCIENCES INC (US) 2023-09-13 EP disclosed
WO-2023114977-A1 S1PR4 RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF TIAKI THERAPEUTICS, INC. (US) 2023-06-22 WO disclosed
US-20210130300-A1 DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2021-05-06 US disclosed
EP-3055288-B1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME (US) 2020-12-16 EP disclosed
EP-3055288-B1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME (US) 2020-12-16 EP disclosed
EP-3744713-A1 DIYHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF Japan Tobacco Inc. (JP) 2020-12-02 EP disclosed
CN-107001286-B Dihydropyrimidine-2-one compounds and medicinal use thereof 日本烟草产业株式会社 2020-07-07 CN disclosed
EP-3231793-B1 DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF JAPAN TOBACCO INC (JP) 2020-03-11 EP disclosed
WO-2015051725-A1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
WO-2015051725-A1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
US-8722656-B2 Cephalosporins useful as antibacterial agents ZOETIS LLC (US) 2014-05-13 US disclosed
EP-2705044-A1 NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS ZOETIS LLC (US) 2014-03-12 EP disclosed
WO-2012150520-A1 NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS PFIZER INC. (US) 2012-11-08 WO disclosed
US-20120283237-A1 NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS PFIZER INC. (US) 2012-11-08 US disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 US disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 US disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 EP disclosed
WO-2010126030-A1 SPIROIMIDAZOLONE DERIVATIVE 中外製薬株式会社 (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 ACHE 3850/4885SHBG 3213/4885ALDH1A1 836/4885
US-20210130300-A1 DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF REN, PKD2, ALPI ACHE 3467/4885SHBG 1309/4885ALDH1A1 132/4885
US-20230373932-A1 DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF REN, PKD2, ALPI ACHE 3467/4885SHBG 1309/4885ALDH1A1 132/4885
US-20120283237-A1 NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS CIAPIN1, CLSPN, MRPL21 ACHE 3409/4885SHBG 3627/4885ALDH1A1 3155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.